☰

Paul Grootendorst - Publications

Affiliations: 
Pharmaceutical Sciences University of Toronto, Toronto, ON, Canada 
Area:
Public Health, Epidemiology, Commerce-Business Economics
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Moradpour J, Shajarizadeh A, Carter J, Chit A, Grootendorst P. The impact of national income and vaccine hesitancy on country-level COVID-19 vaccine uptake. Plos One. 18: e0293184. PMID 37917650 DOI: 10.1371/journal.pone.0293184  0.591
2023 Moradpour J, Chit A, Besada-Lombana S, Grootendorst P. Overview of the global vaccine ecosystem. Expert Review of Vaccines. 22: 749-763. PMID 37608523 DOI: 10.1080/14760584.2023.2250433  0.583
2021 Loiacono MM, Nelson CB, Grootendorst P, Webb MD, Lee Hall L, Kwong JC, Mitsakakis N, Zulueta S, Chit A. Impact of a peer comparison intervention on seasonal influenza vaccine uptake in community pharmacy: A national cluster randomized study. Journal of the American Pharmacists Association : Japha. PMID 33931353 DOI: 10.1016/j.japh.2021.04.004  0.581
2020 Loiacono MM, Mitsakakis N, Kwong JC, Gomez GB, Chit A, Grootendorst P. Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in England. Jama Network Open. 3: e207743. PMID 32597991 DOI: 10.1001/jamanetworkopen.2020.7743  0.589
2020 Loiacono MM, Mahmud SM, Chit A, van Aalst R, Kwong JC, Mitsakakis N, Skinner L, Thommes E, Bricout H, Grootendorst P. Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: An age-stratified retrospective cohort study. Vaccine: X. 4: 100054. PMID 32072152 DOI: 10.1016/J.Jvacx.2020.100054  0.594
2019 Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases. 14: 12. PMID 30630499 DOI: 10.1186/S13023-018-0990-4  0.369
2018 Grootendorst P, Shim M, Falconi A, Robinson T, Lexchin J. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. International Journal of Health Services : Planning, Administration, Evaluation. 20731418789610. PMID 30040005 DOI: 10.1177/0020731418789610  0.322
2018 Grootendorst P, Shim M, Tieu J. Uptake and impact of regulated pharmacy technicians in Ontario community pharmacies. Canadian Pharmacists Journal : Cpj = Revue Des Pharmaciens Du Canada : Rpc. 151: 197-202. PMID 29796133 DOI: 10.1177/1715163518768009  0.302
2017 Hollis A, Grootendorst P. A comparison of mechanisms for setting generic drug prices in Canada Journal of Generic Medicines. 13: 1741134316669967. DOI: 10.1177/1741134316669967  0.338
2016 Chit A, Lee JK, Shim M, Nguyen VH, Grootendorst P, Wu J, Van Exan R, Langley JM. Economic Evaluation of Vaccines in Canada: A Systematic Review. Human Vaccines & Immunotherapeutics. 0. PMID 26890128 DOI: 10.1080/21645515.2015.1137405  0.611
2015 Chit A, Chit A, Papadimitropoulos M, Krahn M, Parker J, Grootendorst P. The opportunity cost of capital: development of new pharmaceuticals. Inquiry : a Journal of Medical Care Organization, Provision and Financing. 52. PMID 25933615 DOI: 10.1177/0046958015584641  0.588
2015 Shajarizadeh A, Grootendorst P, Hollis A. Newton’s First Law as Applied to Pharmacies: Why Entry Order Matters for Generics International Journal of the Economics of Business. 22: 201-217. DOI: 10.1080/13571516.2015.1045746  0.309
2014 Chit A, Parker J, Halperin SA, Papadimitropoulos M, Krahn M, Grootendorst P. Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines. Vaccine. 32: 3336-40. PMID 23830976 DOI: 10.1016/J.Vaccine.2013.06.055  0.636
2012 Grootendorst P, Bouchard R, Hollis A. Canada's laws on pharmaceutical intellectual property: the case for fundamental reform. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 184: 543-9. PMID 22065362 DOI: 10.1503/Cmaj.110493  0.302
2011 Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy (Amsterdam, Netherlands). 100: 4-17. PMID 21256615 DOI: 10.1016/J.Healthpol.2010.12.002  0.345
2011 Grootendorst P, Hollis A, Levine DK, Pogge T, Edwards AM. New approaches to rewarding pharmaceutical innovation. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 183: 681-5. PMID 21149519 DOI: 10.1503/Cmaj.100375  0.302
2009 Grootendorst P. How should we support pharmaceutical innovation? Expert Review of Pharmacoeconomics & Outcomes Research. 9: 313-20. PMID 19670991 DOI: 10.1586/Erp.09.34  0.328
2009 Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P. The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 847-56. PMID 19490554 DOI: 10.1111/J.1524-4733.2009.00532.X  0.364
2007 Grootendorst P, Di Matteo L. Response to pazderka and schroeder. Healthcare Policy = Politiques De Santé. 2: 95-6. PMID 19305723 DOI: 10.12927/Hcpol.2007.18705  0.306
2007 Grootendorst P, Matteo LD. The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada. Healthcare Policy = Politiques De Santé. 2: 63-84. PMID 19305720 DOI: 10.12927/Hcpol.2007.18677  0.371
2007 Marshall DA, Willison DJ, Grootendorst P, LeLorier J, Maclure M, Kulin NA, Sheehy OE, Warren L, Sykora K, Rahme E. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada. Health Policy (Amsterdam, Netherlands). 84: 1-13. PMID 17570558 DOI: 10.1016/J.Healthpol.2007.04.010  0.352
2006 Grootendorst P, Stewart D. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Health Economics. 15: 735-42. PMID 16498702 DOI: 10.1002/Hec.1103  0.357
2006 Marshall D, Gough J, Grootendorst P, Buitendyk M, Jaszewski B, Simonyi S, Jivraj F, Macleod S. Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis. Journal of Health Services Research & Policy. 11: 13-20. PMID 16378528 DOI: 10.1258/135581906775094253  0.311
2005 Contoyannis P, Hurley J, Grootendorst P, Jeon SH, Tamblyn R. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Economics. 14: 909-23. PMID 16127675 DOI: 10.1002/Hec.1041  0.36
2005 Alan S, Crossley TF, Grootendorst P, Veall MR. Distributional effects of 'general population' prescription drug programs in Canada Canadian Journal of Economics. 38: 128-148. DOI: 10.1111/J.0008-4085.2005.00272.X  0.352
2004 Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Medical Care. 42: 653-60. PMID 15213490 DOI: 10.1097/01.Mlr.0000129497.10930.A2  0.37
2004 Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. International Journal of Health Services : Planning, Administration, Evaluation. 34: 101-22. PMID 15088676 DOI: 10.2190/4M3E-L0Yf-W1Td-Ekg0  0.367
2003 Grootendorst P, Palfrey D, Willison D, Hurley J. A review of the comprehensiveness of provincial drug coverage for Canadian seniors Canadian Journal On Aging. 22: 33-44. DOI: 10.1017/S0714980800003718  0.366
2002 Alan S, Crossley TF, Grootendorst P, Veall MR. The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada. Journal of Health Economics. 21: 805-26. PMID 12349883 DOI: 10.1016/S0167-6296(02)00012-7  0.338
2001 Schneeweiss S, Maclure M, Walker AM, Grootendorst P, Soumerai SB. On the evaluation of drug benefits policy changes with longitudinal claims data: The policy maker's versus the clinician's perspective Health Policy. 55: 97-109. PMID 11163649 DOI: 10.1016/S0168-8510(00)00120-2  0.334
Show low-probability matches.